AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03086655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tel-me-box with reminder features
Description: Participants will meet with a study staff member to go over their daily routines, including their pill taking schedule, and to work out a plan for tailored reminders. The participant will choose from the reminders available and convey their preferences regarding when reminders should be sent for the TMB. Preferences will be stored in an online secure database. If requested by the participant, the reminder schedule and type of reminder can be reprogrammed by study staff via an online portal. When the reminder is reprogrammed the TMB receives a new configuration SMS to update the device reminder settings.
Study NCT03086655 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tel-me-box
Description: Participants receive tel-me-box device with no reminder features added.
Study NCT06582680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambient Heat
Description: Subjects will spend 3-hours in a heat chamber at 41°C and 40% humidity.
Study NCT06207383 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Atrial fibrillation ablation
Description: Catheter ablation of atrial fibrillation with pulmonary vein isolation (using technique of operator's choice, with additional lesions if deemed necessary)
Study NCT05746585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Talk Web-based resources
Description: Educational videos and podcasts for parents and their sons
Study NCT05163678 — intervention group
Intervention type: OTHER
Intervention: monitoring naturalistic of cohort
Description: Assessment at the start of care in the Relais (T0), at the end (T1) and 6 months later (T6).
Study NCT05890781 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy
Study NCT05890781 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fresh tumor sample
Description: Fresh tumor sample
Study NCT05890781 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: Blood sample in heparin tubes (highly recommended), to be collected before starting treatment or as soon as hematological recovery has been reached
Study NCT05890781 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Healthy tissue from the tumor
Description: Healthy tissue from the tumor site whenever possible
Study NCT05158972 — intervention group
Intervention type: DRUG
Intervention: Dymista
Description: 1 spray per nostril twice daily up to four weeks
Study NCT05890781 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Spinal cerebrospinal fluid (SCF)
Description: Spinal cerebrospinal fluid (SCF) whenever possible
Study NCT06357065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active transport educational program based on the ecological model
Description: The intervention is structured according to the following units: Unit I: benefits of physical activity on health and healthy habits in schoolchildren; Unit II: Active Transportation: Experiences from other countries; Unit III: Analysis of the environmental characteristics of the school environment of each establishment; and Unit VI: Road safety for pedestrians and cyclists. This last topic will be broken down considering analysis and prevention of accidents with automobiles, pedestrian regulations, signaling, and cyclist safety. The sessions of the last month of intervention (November) will include practical walking activities in the school environment (outside the school). Depending on the possibilities of each school, cycling sessions will be included.
Study NCT05938413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wise App with medication adherence reminders
Description: The Intervention group will receive the Wise App that delivers medication adherence reminders.
Study NCT05938413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW Sessions
Description: The Intervention group will complete sessions with a community health worker (CHW).
Study NCT06257459 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subinguinal varicocelectomy
Description: exision or preservation of spermatic cord lipoma during subinguinal varicocelectomy
Study NCT05744505 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1565nm Non-ablative Fractional Laser
Description: Every 3 weeks
Study NCT05744505 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Every 3 weeks
Study NCT05670600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot and ankle exercise
Description: Foot and Ankle Exercise Phase~1. Pulling the foot upwards from the ankle~2. Bending the foot down from the ankle~3. Spreading the feet like a fan, moving the toes in and out to the right and left~4. Circle drawing exercise with ankle~5. Towel folding exercise~6. Bottle rolling exercise under the feet (The water in the bottle will be warm tap water)
Study NCT05069129 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)
Description: Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08) in the deltoid muscle of the upper arm
Study NCT05186467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intraperitoneal Magnesium sulfate
Description: Intraperitoneal (IP) group will receive 100 ml normal saline infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline intraoperatively then intraperitoneal wash of 100 ml normal saline containing 30 mg/kg MgSO4 at the end of laparoscopy.
Study NCT05186467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous magnesium sulfate
Description: Intravenous (IV) group will receive 100 ml normal saline containing MgSO4 30 mg/kg infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline containing MgSO4 (8mg/kg) intraoperatively then intraperitoneal wash using 100 ml normal saline at the end of laparoscopy.
Study NCT05690295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged resistance-type exercise training
Description: All volunteers will be subjected to 12 weeks of whole-body resistance-type exercise training (3x/wk).
Study NCT06538623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome Irinotecan Injection II combined with Oxaliplatin, Fluorouracil, Leucovorin
Description: Liposome Irinotecan: 60 mg/m², Oxaliplatin: 85 mg/m², Fluorouracil: 2400 mg/m², Leucovorin: 400 mg/m², every 3 weeks (Q3W), administered via hepatic arterial infusion (HAIC);
Study NCT06538623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegodor
Description: Tegodor: 40 mg per dose, twice daily for seven days, every 3 weeks (Q3W), taken orally.
Study NCT05550012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-dose CT
Description: those patients undergo low-dose liver CT in portal vein and delayed phase.
Study NCT05676892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed, and the skin was sutured
Study NCT05069129 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine (Vero cells)
Description: Intramuscular injection of Inactivated COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm
Study NCT05069129 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3 doses Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)
Description: Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08) in the deltoid muscle of the upper arm on 0，30，60 days
Study NCT06198907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golidocitinib
Description: Daily dosing of golidocitinib
Study NCT06198907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab, 200mg, intravenous, every 3 weeks.
Study NCT06198907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platinum doublet chemotherapy
Description: Pemetrexed or nab-paclitaxel +carboplatin, intravenous, every 3 weeks for 2 cycles
Study NCT05228782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HOW R U? Intervention
Description: HOW RU? intervention uses trained volunteer peers to provide strength-based support sessions weekly for 12 weeks.
Study NCT06537661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Virtual reality (VR): is the artificial construction of a 3D environment viaThe VR glasses which were the source of visual and auditory feedback, were connected by Bluetooth to a mobile phone and all the videos of selected tasks.
Study NCT06537661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional exercises
Description: Active mobility exercises (jaw opening 6 times of 30 s; lateralization 10 times of 5 s; protrusion 10 times Of 5 s). Self-massage masticatory Muscles, After each session.~* Isometric contraction exercises Were included (3 times of 10 s)
Study NCT06515665 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic foot orthosis
Description: They will be asked to behaviorally wear this shoe and perform the exercises daily for 6 weeks.
Study NCT04647058 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cubital tunnel release
Description: The control group will undergo cubital tunnel release in situ. In cases of preoperative or intraoperative ulnar nerve instability, anterior transposition of the ulnar nerve will be performed.
Study NCT04647058 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supercharged end-to-side (SETS) nerve transfer
Description: The SETS group will undergo the same procedure as described above, with the addition of the SETS procedure consisting of a end-to-side transfer of the anterior interosseous nerve to the ulnar nerve motor branch. Decompression of Guyon's canal during the SETS procedure is at the discretion of the treating surgeon.
Study NCT04699331 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
Study NCT04699331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
Study NCT04699331 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
Study NCT05576116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy AND Pancreas after Kidney Transplantation (Staggered Approach)
Description: Participants will undergo sleeve gastrectomy a minimum of 3 months prior to Pancreas Transplant. SG will be performed using the standard technique.~Pancreas transplant will be performed as per standard procedure.
Study NCT05576116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Sleeve Gastrectomy and Pancreas transplantation
Description: Simultaneous SG and pancreas transplantation
Study NCT06202638 — intervention group
Intervention type: DEVICE
Intervention: HemoSphere monitor with Acumen Hypotension Prediction Index Software
Description: Two concomitant courses of intraoperative data will be recorded: 1. the arterial waveform and pressure on the standard hemodynamic patient monitor and 2. the data from the HemoSphere monitor with Acumen Hypotension Prediction Index Software
Study NCT05287191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate and then Digoxin
Description: We will test MgSO4 and then digoxin IV (in 3 divided dose) as second line therapy with amiodarone IV as third line. Digoxin will be protocolised to commence between 30 minutes and 12 hours after MgSO4 if fast Atrial Fibrillation persists as initially designated (dose 1). Undiluted IV digoxin (12 mcg/kg) will be administered in 3 divided doses (6, 3 and 3 mcg/kg) separated by approximately 6 hrs (i.e. dose 1 at 30 mins - 12 hours after MgSO4, followed by dose 2 at -6 hrs and dose 3 at the approximately 12 hrs). Patients with renal dysfunction (creatinine clearance \<60 ml/min measured by the Modification of diet in renal disease formula) will receive a reduced dose of 8 mcg/kg in 3 divided doses (4, 2, and 2 mcg/kg) separated by the same time intervals. In the trial intervention group, amiodarone will be given approximately 120 mins after digoxin if necessary whilst completing the digoxin dose. Amiodarone as a 150 mg infusion over 10 minutes followed by 900 mg over 24 hours.
Study NCT05287191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: We will test Amiodarone (150mg IV then 900mg IV over the next 24 hours ) as first line treatment in the standard of care group. No more than 2g MgSO4 be delivered over 2 hours maximum for this group in the first 24 hours after randomisation unless clinically indicated for measured hypomagnesaemia (a value below the index hospital laboratories lower limit of normal).
Study NCT04672005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox alternating with Gemcitabine-nab-Paclitaxel
Description: modified Folfirinox every 2 weeks and biweekly Gemcitabine plus Nab-Paclitaxel
Study NCT05562232 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate
Description: Follows
Study NCT05562232 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Creatine Monohydrate
Description: Follows
Study NCT05472259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nanoliposomal irinotecan
Description: In the control arm (Naliri) a dose of 70mg/m² is administered in combination with 5FU and leucovorin In the investigational arm (Nalirinox) a dose of 50mg/m² is administered in combination with 5FU, leucovorin and oxaliplatin
Study NCT05334524 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesiotaping with combined chain exercises
Description: 3 Kinesiotape strips will be applied: 2 Y-strips with a length of approximately 20 cm and an anchor of 2 cm and a single longitudinal section (1 I-strip). Tails of the quadriceps strip were applied to the patella, wrapping the patella medially and laterally with 25% tension and the (I-strip) will be applied with 75% tension.~Combined chain exercises will apply with 10 secs hold with 10 repetitions which will include quadriceps setting, SLR, full arc extension, cycling in the air, wall slides and step-up and step-down exercises
Study NCT05334524 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesiotaping
Description: 3 Kinesiotape strips will be applied: 2 Y-strips with a length of approximately 20 cm and an anchor of 2 cm and a single longitudinal section (1 I-strip). Tails of the quadriceps strip were applied to the patella, wrapping the patella medially and laterally with 25% tension and the (I-strip) will be applied with 75% tension
Study NCT06262763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Therapy
Description: High-intensity
Study NCT06262763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional exercises
Description: Hamstring and piriformis stretch, plank exercises and bird dog exercise
Study NCT06262763 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Traditional exercises
Description: Hamstring and piriformis stretch, plank exercises and bird dog exercise
Study NCT06262763 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo laser
Description: Not directed radiation to participant
Study NCT00944060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Study NCT05472259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoliposomal irinotecan
Description: In the control arm (Naliri) a dose of 70mg/m² is administered in combination with 5FU and leucovorin In the investigational arm (Nalirinox) a dose of 50mg/m² is administered in combination with 5FU, leucovorin and oxaliplatin
Study NCT05021900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenalisib 800mg
Description: Tenalisib will be administered 800mg BID, orally
Study NCT05472259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 FU
Description: In the control arm (Naliri) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan and leucovorin In the investigational arm (Nalirinox) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan, leucovorin and oxaliplatin
Study NCT05472259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 FU
Description: In the control arm (Naliri) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan and leucovorin In the investigational arm (Nalirinox) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan, leucovorin and oxaliplatin
Study NCT05021900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenalisib 1200mg
Description: Tenalisib will be administered 1200mg BID, orally
Study NCT05527301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus Fermentum
Description: Lactobacillus Fermentum
Study NCT05527301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05198414 — intervention group
Intervention type: OTHER
Intervention: Focus group
Description: Qualitative research methodology with healthcare workers
Study NCT05252273 — intervention group
Intervention type: OTHER
Intervention: Observational, No intervention
Description: Open-label observational study that will evaluate the reliability and responsiveness of patient-reported symptoms and endoscopic and histologic items for assessing pouchitis disease activity in 43 patients undergoing standard of care (SOC) antibiotic therapy.
Study NCT06565897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test regimen
Description: toothpaste \& manual toothbrush
Study NCT06565897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control regimen
Description: toothpaste \& manual toothbrush
Study NCT04766970 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ADOS-2 Module 4
Description: Assessment in person using standardized Autism Diagnostic Observation Schedule, 2nd Edition (ADOS-2) Module 4.
Study NCT04766970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Telehealth ADOS-2 Module 4
Description: Assessment via telehealth/teleconference platform using an adapted ADOS-2, Module 4 assessment protocol.
Study NCT05219513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7443904
Description: RO7443904 will be administered by subcutaneous (SC) or IV infusion on Cycle (C) 1 Day (D) 10, C2D3, and C2D8. From C3 onward, RO7443904 will be given every 3 weeks (Q3W), for up to 12 cycles (C = 21 days).
Study NCT05219513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab will be administered through IV infusion starting with step-up dosing (2.5 mg/10 mg/30 mg) on C1D1, C1D8, and C2D1. Starting in Cycle 3, glofitamab will be given in 30 mg doses every three weeks (Q3W) with RO7443904, for up to 12 cycles (Cycle = 21 days).
Study NCT05219513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered once through IV infusion, at a 1 g dose in Cycle 1, on either Day -7, -4, or -3 (C1D-7, C1D-4, C1D-3).
Study NCT05219513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
Study NCT04779242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline
Description: IV for injection, oral tablets
Study NCT04779242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: IV solution, oral tablets
Study NCT04387487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimedia video information
Description: During pre anesthesia visit after regular pre anesthesia check up patient will be asked to fill the Hamilton scoring questionnaire about anxiety.~After this a multimedia video information about spinal anesthesia of around 6 minutes will be shown to the intervention group during pre anesthesia visit. This video will contain explanation about how spinal anesthesia procedure is conducted. Patient will be allowed to ask questions.~On the day of surgery in the pre surgical area again Hamilton scoring questionnaire will be asked with the patients to check the level of anxiety.
Study NCT05472259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: In the control arm (Naliri) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan and 5FU In the investigational arm (Nalirinox) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and oxaliplatin
Study NCT05472259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: In the control arm (Naliri) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan and 5FU In the investigational arm (Nalirinox) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and oxaliplatin